Low Circulating Levels of Insulin‐Like Growth Factors and Testosterone in Chronically Institutionalized Elderly Men

Abbasi, Adil A.; Drinka, Paul J.; Mattson, Dale E.; Rudman, Daniel

doi:10.1111/j.1532-5415.1993.tb06764.x

Cited by 88 publications

(80 citation statements)

References 42 publications

(65 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This event is associated with multiple neuroendocrinemetabolic deficiencies that can explain the progressive change from the anabolic state to the catabolic state in this population (Abbasi et al 1993;Morales et al 1998). Besides this, the decreased levels of other hormones like IGF-1 and GH also contribute to the development of these deficiencies (Sattler et al 2009).…”

Section: Introductionmentioning

confidence: 99%

Effects of testosterone on lean mass gain in elderly men: systematic review with meta-analysis of controlled and randomized studies

Neto

Gama

Rocha

et al. 2015

AGE

View full text Add to dashboard Cite

The objective of this study was to evaluate the effects of steroid anabolic androgenic hormones use on lean mass gain in elderly men through a systematic review with a meta-analysis of randomized controlled studies. We systematically searched PubMed database until 4th October 2013. We included randomized placebo-controlled trials (RCT) that studied testosterone replacement therapy in men over 60 years of age, with total testosterone levels ≤550 ng/dl, observing gains in weight, lean mass tissue and fat mass as outcome. We excluded duplicated studies, studies which mixed men and women, and studies using weak androgens such as dehydroepiandrosterone or androstenedione. The initial search yielded 2681 articles, of which 26 were selected for full text analysis. In the end, 11 studies were included. However, 3 studies were not included in the metaanalysis. Meta-analysis showed that mean weight increased (lean mass), ranging from 1.65 (95 % CI, AGE (2015) ) kg, although it was heterogeneous (I 2 =98 %). Effect estimate was 3.59 [2.38-4.81]. Androgen therapy decreased fat mass; effect estimate was −1.78 [−2.57, −0.99] that analysis had also a high level of heterogeneity (I 2 =81 %). The results suggest that testosterone replacement therapy is able to increase muscle mass in elderly men and that is affected by the time that the treatment is carried out and the method of administration of the drug.

show abstract

Section: Introductionmentioning

confidence: 99%

Effects of testosterone on lean mass gain in elderly men: systematic review with meta-analysis of controlled and randomized studies

Neto

Gama

Rocha

et al. 2015

AGE

View full text Add to dashboard Cite

show abstract

“…36,37 The decrease in bone mass with advancing age may be associated with declining insulinlike growth factor (IGF-1) levels as well as T concentrations. 38 Partly by facilitating commitment of pluripotent mesenchymal cells, androgens may also foster skeletal-muscle hypertrophy and hence promote lean body mass. 39 Exogenous T increases satellitecell populations within muscles, with attendant rises in numbers of myoblasts and large-myofiber myonuclei, as well as formation of larger motoneurons.…”

Section: Effects Of Testosterone On Body Compositionmentioning

confidence: 99%

Male hypogonadism. Part II: etiology, pathophysiology, and diagnosis

Seftel

2005

Int J Impot Res

View full text Add to dashboard Cite

Male hypogonadism has a multifactorial etiology that includes genetic conditions, anatomic abnormalities, infection, tumor, and injury. Defects in the hypothalamic-pituitary-gonadal axis may also result from type II diabetes mellitus and treatment with a range of medications. Circulating testosterone levels have been associated with sexual function, cognitive function, and body composition. Apart from reduced levels of testosterone, clinical hallmarks of hypogonadism include absence or regression of secondary sex characteristics, reduced fertility (oligospermia, azoospermia), anemia, muscle wasting, reduced bone mass (and bone mineral density), and/or abdominal adiposity. Some patients, particularly those with partial androgen deficiency of the aging male, also experience sexual dysfunction, reduced sense of vitality, depressed mood, increased irritability, difficulty concentrating, and/or hot flushes in certain cases of acute onset. As many patients with male hypogonadism-like patients with erectile dysfunction-do not seek medical attention, it is important for clinicians to be acquainted with the signs and symptoms of hypogonadism, and to conduct appropriate laboratory testing and other assessments to determine the causes and inform the treatment of this condition.

show abstract

“…These changes in body composition, physical function and substrate metabolism are related to decreased production of testosterone and growth hormone (GH) in older persons 5 . Approximately 25-30% of men over 60 years-of-age have low levels of testosterone 6 that may be associated with sarcopenia, muscle weakness or frailty, central adiposity, increased CVD risks, and mortality [7][8][9] .…”

Section: Introductionmentioning

confidence: 99%

“…Approximately 25-30% of men over 60 years-of-age have low levels of testosterone 6 that may be associated with sarcopenia, muscle weakness or frailty, central adiposity, increased CVD risks, and mortality [7][8][9] . Declines in GH synthesis and release have also been associated with similar age-related co-morbidities including body adiposity and the metabolic syndrome [10][11][12] even in persons with normal testosterone levels 5 . Levels of IGF-1, a mediator of several but not all anabolic effects of GH, continue to decline into the 8 th and 9 th decades 5 and are associated with loss of lean body mass (LBM) and increases in adiposity 10 .…”

Section: Introductionmentioning

confidence: 99%

“…Declines in GH synthesis and release have also been associated with similar age-related co-morbidities including body adiposity and the metabolic syndrome [10][11][12] even in persons with normal testosterone levels 5 . Levels of IGF-1, a mediator of several but not all anabolic effects of GH, continue to decline into the 8 th and 9 th decades 5 and are associated with loss of lean body mass (LBM) and increases in adiposity 10 .…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Durability of the Effects of Testosterone and Growth Hormone Supplementation in Older Community Dwelling Men: The HORMA Trial.

Sattler¹,

Bhasin²,

He³

et al. 2010

The Endocrine Society's 92nd Annual Meeting, June 19–22, 2010 - San Diego

View full text Add to dashboard Cite

Objectives-Determine the durability of anabolic effects and adverse events (AEs) after stopping testosterone and growth hormone supplementation in older men.Design-Secondary analysis of a double-masked, randomized controlled trial of testosterone gel (5g or 10g/daily) plus rhGH (0, 3, or 5ug/kg/day) with follow-up of outcomes 3-months later.Participants-108 community-dwelling 65-90 year-old-men.Measurements-Testosterone and IGF-1 levels, body composition (DEXA), 1-repetition maximum (1-RM) strength, stair-climbing power, quality-of-life (QOL) and activity questionnaires, AEs.Results-Despite improvements in body composition during treatment, residual benefits 3-months later (week-28) were variable. For participants with improvements exceeding their week-17 median changes, benefits were sustained at week 28 for lean body mass (LBM, 1.45±1.63kg, 45% of week-17 values, p<0.0001-vs-baseline), appendicular skeletal muscle mass (ASMM, 0.71±1.01kg, 42%, p<0.0001), total fat (-1.06±2.18kg, 40%, p<0.0001,), and trunk fat (-0.89±1.42kg, 50%, p<0.0001,); retention of ASMM was associated with greater week-16 protein intake (p=0.01). For 1-RM strength, 39%-43% of week-17 improvements (p≤0.05) were retained and associated with better week-17 strength (p<0.0001), change in testosterone from week-17-to-28 (p=0.004) and baseline PASE (p=0.04). Framingham 10-year cardiovascular risks were low Conclusions-Durable improvements in muscle mass, strength, and fat mass were retained 3-months after discontinuing hormone supplementation in participants with greater than median body composition changes during treatment, but not in others with smaller gains. AEs largely resolved after intervention discontinuation. Additional strategies may be needed to sustain or augment muscle mass and strength gains achieved during short-term hormone therapy.

show abstract

Low Circulating Levels of Insulin‐Like Growth Factors and Testosterone in Chronically Institutionalized Elderly Men

Cited by 88 publications

References 42 publications

Effects of testosterone on lean mass gain in elderly men: systematic review with meta-analysis of controlled and randomized studies

Effects of testosterone on lean mass gain in elderly men: systematic review with meta-analysis of controlled and randomized studies

Male hypogonadism. Part II: etiology, pathophysiology, and diagnosis

Durability of the Effects of Testosterone and Growth Hormone Supplementation in Older Community Dwelling Men: The HORMA Trial.

Contact Info

Product

Resources

About